FDA Approves NeurogesX's Qutenza After the market closed on November 16, 2009, NeurogesX (NGSX) announced that the U.S. FDA had approved Qutenza (capsaicin patch) for the management of neuropathic pain due to postherpetic neuralgia (PHN).  We expect management to spend the next several months preparing for the launch by facilitating reimbursement procedure, establishing distribution channels, hiring and training the specialty sales force, and conducting the manufacturing for commercial supply. Key to our bullish sales forecast for the drug will be establishing a permanent reimbursement code for both the product and application, as Qutenza requires administration by a physician or healthcare professional. Qutenza is a cutaneous (skin) patch designed to treat peripheral neuropathic pain conditions. The Qutenza patch provides a pure high concentration (8%) of a synthetic capsaicin, known as trans­-capsaicin, directly to the site of pain via a rapid-delivery cutaneous delivery system designed to provide ...

On June 22, 2009, NeurogesX (NGSX) announced that it has entered into a development and commercialization partnership for Qutenza, the company's cutaneous patch for neuropathic pain, with Astellas Pharmaceuticals. NeurogesX has licensed for commercialization Qutenza in all 27 EU member states, plus Iceland, Norway, Liechtenstein and Switzerland, along with the Middle East and Africa.Astellas has also agreed to fund the required additional studies as requested by the European Commission, which include a long-term safety program in on-label indications. In return, Astellas has agreed to pay NeurogesX an upfront payment for Qutenza of e30 million ($42 million).We expect that NeurogesX will recognize this payment over the life of the agreement. Astellas has also purchased an option to co-develop NGX-1998, the company's liquid formulation, for e5 million ($7 million). In addition to these upfront payments, Astellas has also committed e70 million ($97 million) in ...

Today a Polish magazine is publishing a version of the attached extended article, will update with link soon.

"Power, Carry out Your Laws!"

By Robert Amsterdam

These words stated by Mikhail Khodorkovsky at the start of a second show trial against him in Moscow this March should echo in the ears not only of the country's leadership, but also of all those who wish to engage constructively with Russia. For a leadership that does not respect its own laws is one that no one can trust - not its own citizens and not its foreign partners.

On the night this second sham prosecution against Khodorkovsky began, a prominent 67-year-old human rights activist was savagely beaten for among other things supporting the release of Russia's most famous political

...

BALZERS, Liechtenstein - May 28 2009 - Today, Oerlikon Systems (SWX:OERL) demonstrates for the first time SOLARIS, a revolutionary production solution that simplifies the manufacturing of crystalline solar cells.

Zevotek, Inc. was pleased to announce this morning that it has completed an overseas marketing and sales agreement with Media Shop. The sales agreement covers the territories of Germany, Austria, Switzerland, Slovakia, Hungry, Liechtenstein, Romania, Poland and the Czech Republic.

The company stated, “With Media Shop’s proven sales and marketing track record we are very excited to be working with them in this endeavor. With their knowledge of the foreign countries that they have chosen to penetrate Zevotek is confident that Media Shop will generate sales exceeding the numbers that are laid out as the minimums in the contract.”

According to a press release issued last week, this agreement calls for 60,000 bulbs over a year period. Zevotek believes the number of bulbs this deal calls for is only a starting point as Media Shop has a strong track record and will be able to

...

For weeks now the liberal world media dutifully has been repeating dire threats against so-called “tax havens” from the big spending, high taxing, anti-tax competition likes of Germany’s Merkel and France’s Sarkosy.

Even President Obama allowed his less than impressive Secretary of the Treasury to make some noise against tax havens.

The orchestrated battle of words hurled at offshore financial centers got so heated that British PM Gordon Brown felt obliged to demand for “the end of tax havens.”

This belated anti-tax haven baloney comes from Her Majesty’s first minister whose government is in charge (and has been for a decade) of the United Kingdom’s many tax havens in its overseas territories (Bermuda, the Cayman Islands, British Virgin Islands, the Turks & Caicos) and its Crown Dependencies (the Channel Islands of Jersey and Guernsey and the Isle of Man), plus Gibraltar.

Does the Rt. Hon. Gordon believe that the

...

IDM Pharma, Inc. announced that the European Commission has formally authorized MEPACT® (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor. MEPACT can now be marketed in the 27 Member States of the European Union, as well as in Iceland, Liechtenstein and Norway.

“Today’s approval of MEPACT is a significant milestone for physicians and patients in Europe, giving them access to the first new osteosarcoma treatment option in 20 years,” commented Timothy P. Walbert, president and chief executive officer, IDM Pharma. “As our lead product candidate and first to receive approval, this is also a major milestone for IDM Pharma. We look forward to amending the New Drug Application (NDA) for mifamurtide in the United States and continuing to work toward bringing this important treatment to market in the U.S.”

The approval was based on the Phase 3 MEPACT trial (INT-0133), the

...

No follow through on the Eurozone bond idea…  Mirror, mirror on the wall…  AIG to set record for losses…  And Now… Today’s Pfennig! Well… The Eurozone bond story that I brought to you yesterday failed to materialize yesterday, recall I told you that Germany was against the idea, and this failure to launch… Pushed the euro back down from the high 1.29 handle late Friday afternoon, to the 1.27 handle this morning… I see where the euro has rebounded back above 1.28 as I went through the explanation of Shrove Tuesday, so at least it shows a pulse every now and then!

The Risk Takers have crawled back under rocks and into the walls again, as Risk Aversion weighs heavily on the currencies… I saw a headline this morning that made me laugh out loud… Some writer believes that the “Dollar Is Best Looker in Ugly-Currency Parade”… Hmmm, apparently he didn’t

...

div align=”justify”I went long equity and oil futures last week emstrongin anticipation of a sustained and significant rally in the next few weeks, in the order of 25% through year end/strong/em. As I noted on Friday, the Samp;P hit its 25 year moving average for only the third time since 1942 on Thursday; the Dow was trading 33% below its 200 day moving average. emstrongEquities have become technically oversold to a degree seen only once every few decades./strong/em On 24 July I explained: em’We’re now probably midway through a structural cycle that may last to 2015 or so. Another way of looking at it is that returns were ‘front loaded’ during the huge bull market from 1983 to 2000, making the entry point crucial for successful investing.’/em That analysis stands, and the ultimate low for the Samp;P may be something like 600 in 2009, depending on the brutality of this …

Osteosarcoma is a childhood cancer, usually affecting the bones of children and young adults during adolescent growth spurts. Most of the tumors are found in large bones such as the femur, tibia and humerus, though the tumors can occur in any bone. Although fewer than 1,000 new cases are diagnosed in the U.S. each year, the survival rate of children with osteosarcoma has remained at 60-65 percent since the 1980s.

IDM Pharma Inc. (Nasdaq: IDMI) concentrates on developing innovative cancer products that destroy cancer cells by activating immunity or preventing tumor recurrence. The company focuses on reaching full therapeutic and commercial potential for each of its products, including its resectable osteosarcoma treatment.

The company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) released a positive review of IDM’s L-MTP-PuE, or MEPACT, to treat resectable osteosarcoma. The committee also recommended that

...